Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

Nitroimidazole

Chagas Research

  • Target disease: Chagas
  • Partners (since project start)TB Alliance, USA; Auckland University, New Zealand; Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Belgium; WuXi AppTech, China; LSTMH, UK
  • Project start: April 2012
  • Funding (since project start): Department for International Development (DFID), UK; Dutch Ministry of Foreign Affairs (DGIS), the Netherlands; Federal Ministry of Education and Research (BMBF through KfW), Germany; Médecins Sans Frontières/Doctors without Borders, International; Swiss Agency for Development and Cooperation (SDC), Switzerland; Other private foundations and individuals.
  • Project status: Completed

Overall Objective:
  • Generate new drug candidates for the treatment of Chagas to be assessed in clinical trials

An opportunistic approach has been undertaken to assess compounds issuing from the VL-2098 back-up programme (nitroimidazooxazine series) showing activity against T. cruzi in vitro, evaluating the most promising candidates in in vivo models of Chagas disease. Two VL lead back-ups belonging to different sub-series (7-substituted nitroimidazooxazines and PA-824 analogues) are active and have been selected for further assessment against Chagas disease in the new bioluminescence in vivo model at LSHTM.



Last update: August 2015


Tags: Chagas disease
Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License